HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

54.450

-8.000-12.81%

Volume:10.77M

Turnover:611.64M

Market Cap:10.84B

PE:-38.84

High:62.750

Open:61.300

Low:51.750

Close:62.450

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:25.46

T/O Rate:5.44%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.402

ROE:-27.61%

ROA:-9.92%

PB:7.39

PE(LYR):-38.84

PS:52.76

Loading ...

Overview Company News Filings

LEADS BIOLABS-B Granted Listing Approval for H-Share Full Circulation

Leads Biolabs plans Q3 2026 China BLA filing for LBL-024 cancer antibody

Leads Biolabs hosts R&D symposium in Shanghai on immuno-oncology strategy shift

Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility

Simply Wall St.

LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme

Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares

Bulletin Express

Nanjing Leads Biolabs gets CSRC filing notice for H-share full circulation plan

LEADS BIOLABS-B Shares Rise Nearly 3% in Late Trading as Partner Advances LBL-047 Clinical Program

Leads Biolabs Confirms Stable Share Structure and Public-Float Compliance for April 2026

Bulletin Express

Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations

LEADS BIOLABS-B Selects Initial Clinical Indications for LBL-047

Nanjing Leads Biolabs says LBL-047 Phase I trial starts in China for lupus

LEADS BIOLABS-B Shares Climb Over 4% in Afternoon Session as Key Product LBL-024 Nears Launch

Leads Biolabs Calls 15 May 2026 AGM; Reports 2025 Results, Proposes No Dividend and Seeks Fresh Share Issue & Buy-back Mandates

Bulletin Express

Leads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes

Bulletin Express

Nanjing Leads Biolabs publishes ESG report

Leads Biolabs Proposes House-Keeping Amendments to Its Articles of Association, Seeks Shareholder Approval at Upcoming AGM

Bulletin Express

Nanjing Leads Biolabs proposes articles of association amendments for shareholder approval

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Enters Phase Ⅱ Trial With First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

THOMSON REUTERS

LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/09887/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":54.45,"timestamp":1785122130556,"preClose":62.45,"halted":0,"volume":10772000,"delay":0,"changeRate":-0.12810248198558846,"floatShares":198000000,"shares":199000000,"eps":-1.4018327399344388,"marketStatus":"Trading","change":-8,"latestTime":"07-27 11:15:41","open":61.3,"high":62.75,"low":51.75,"amount":611644717,"amplitude":0.176141,"askPrice":54.45,"askSize":300,"bidPrice":54.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.3636009379362268,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1785124800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":62.45,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":25.464824,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.401833,"volumeRatio":25.464824,"shares":199000000,"dividePrice":0,"high":62.75,"amplitude":0.176141,"preClose":62.45,"low":51.75,"week52Low":44.72,"pbRate":"7.39","psRate":"52.76","week52High":97.5,"institutionHeld":0,"latestPrice":54.45,"committee":-0.5,"eps":-1.4018327399344388,"divideRate":0,"volume":10772000,"delay":0,"ttmEps":-1.3636009379362268,"open":61.3,"prevYearClose":51,"prevWeekClose":62.45,"prevMonthClose":49.32,"prevQuarterClose":49.32,"fiveDayClose":64.45,"twentyDayClose":49.58,"sixtyDayClose":81.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-07-24","current":-45.803176,"percent":0.258197,"low":-76.458084,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"high":-30.202688,"avg":-41.824579,"sd":10.124459,"marketCap":12420792910},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910}],"updateTime":1785101419602},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1196445082","title":"LEADS BIOLABS-B Granted Listing Approval for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1196445082","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196445082?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:14","pubTimestamp":1778764451,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B announced that the company has received approval from the Stock Exchange for the listing and trading of approximately 44.3916 million H shares, granted on May 14, 2026.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","IPOS","BK1161","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288039","title":"Leads Biolabs plans Q3 2026 China BLA filing for LBL-024 cancer antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288039","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288039?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:03","pubTimestamp":1778497405,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs set a Q3 2026 filing target in China for LBL-024, a PD-L1/4-1BB bispecific antibody, positioning it as the company’s first potential commercial product with launch expected in 2027.Clinical results have already been generated across multiple studies, with reported outcomes highlighting a manageable safety profile and signs of broad activity in hard-to-treat tumors, including settings typically less responsive to checkpoint inhibitors.Additional readouts will be presented later in 2026, with first-line NSCLC data slated for WCLC in September.ESMO in October is expected to feature pivotal late-line extrapulmonary neuroendocrine carcinoma results, alongside updates in earlier-line disease and other tumor types.Regulatory momentum includes China Breakthrough Therapy Designation, US Fast Track and Orphan Drug designations, and EU Orphan Drug designation, supporting an accelerated path to market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL803GJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09887","BK1161","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288796","title":"Leads Biolabs hosts R&D symposium in Shanghai on immuno-oncology strategy shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288796?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:02","pubTimestamp":1778497375,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs held an R&D symposium in Shanghai under theme “Leads Innovation, Future Forward.”Management outlined a shift to multi-mechanism integration across its immuno-oncology platforms, flagged a first product launch in 2027, guided to 20+ clinical-stage molecules, 4 to 8 late-stage assets, and 3 commercial products by 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via PR Newswire  on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL9NtdkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450208","title":"Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450208","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450208?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:56","pubTimestamp":1778244998,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%.\nSee our latest analysis for Nanjing Leads Biolabs.\nThe latest 1 day share price return of 1.77% and 7 day share price return of 0.75% come after a 59.60% year to date share price gain. The 30 day share price return shows a 10.39% decline, which tempers what still looks like building momentum over the past...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09887","DCF","BK1161","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127882981","title":"LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1127882981","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127882981?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:30","pubTimestamp":1778243428,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176407072","title":"Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1176407072","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176407072?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:25","pubTimestamp":1778243104,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633568314","title":"Nanjing Leads Biolabs gets CSRC filing notice for H-share full circulation plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633568314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633568314?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:13","pubTimestamp":1778242432,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs received a China securities regulator filing notice covering conversion of 44,391,598 unlisted shares held by 23 shareholders into H shares under its H-share full circulation plan.Conversion and listing must be completed within 12 months of filing notice issuance date of April 27, 2026, or filing materials must be refreshed to proceed.Additional filing materials were submitted May 8, 2026 for conversion of 1,221,511 unlisted shares held by one shareholder into H shares.Next step is application to Hong Kong Stock Exchange for conversion and listing, subject to completion of required regulatory procedures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content us","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLpgbst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184233737","title":"LEADS BIOLABS-B Shares Rise Nearly 3% in Late Trading as Partner Advances LBL-047 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1184233737","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184233737?lang=en_us&edition=fundamental","pubTime":"2026-05-08 15:35","pubTimestamp":1778225711,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw an increase of nearly 3% in late trading. At the time of writing, the stock was up 2.65%, trading at HKD 81.3, with a turnover of HKD 49.5042 million. Recently, LEADS...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","VXUS","BK1161","09887","HK0000500386.USD","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164357227","title":"Leads Biolabs Confirms Stable Share Structure and Public-Float Compliance for April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1164357227","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164357227?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:45","pubTimestamp":1778057102,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) submitted its Monthly Return for the period ended 30 April 2026, confirming that there were no movements in either authorised or issued share capital...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175594296","title":"Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations","url":"https://stock-news.laohu8.com/highlight/detail?id=1175594296","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175594296?lang=en_us&edition=fundamental","pubTime":"2026-05-06 09:14","pubTimestamp":1778030064,"startTime":"0","endTime":"0","summary":"Major Developments: LEADS BIOLABS-B (09887) will prioritize the clinical development of LBL-047 for Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis. ASCLETIS-B (01672) will...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","159875","BK4585","160640","000941.SH","01672","HK0000500386.USD","HK0000252152.HKD","06938","BK1116","HK0000252160.HKD","BK1574","01201","BK1515","09887","VXUS","BK1161","399941"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143981897","title":"LEADS BIOLABS-B Selects Initial Clinical Indications for LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=1143981897","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143981897?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:42","pubTimestamp":1778028146,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that its partner, Dianthus Therapeutics (Nasdaq: DNTH), has chosen Sjögren's syndrome (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633097661","title":"Nanjing Leads Biolabs says LBL-047 Phase I trial starts in China for lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2633097661","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633097661?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:30","pubTimestamp":1778027421,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs partner Dianthus Therapeutics prioritized LBL-047 for clinical development in Sjgren’s disease, systemic lupus erythematosus, and dermatomyositis, positioning the asset as a core program for multiple autoimmune indications.Phase I study started in China in December 2025, enrolling healthy volunteers and systemic lupus erythematosus patients, with results not yet presented.Top-line readout from healthy-volunteer cohort expected in 2H 2026, setting up decisions on next clinical steps across prioritized indications.Dianthus completed an upsized underwritten public offering in March 2026 that raised about USD 719 million, strengthening funding for global development.LBL-047 combines two mechanisms intended to reduce autoimmune activity, supporting a potential subcutaneous self-administration regimen with dosing every four weeks or less.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL2PMx5t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","BK4139","HK0000500386.USD","BK1161","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112732538","title":"LEADS BIOLABS-B Shares Climb Over 4% in Afternoon Session as Key Product LBL-024 Nears Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1112732538","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112732538?lang=en_us&edition=fundamental","pubTime":"2026-04-27 14:58","pubTimestamp":1777273098,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its shares rise more than 4% during the afternoon trading session. At the time of writing, the stock was up 2.28%, trading at HKD 85.3, with a turnover of HKD 37.3549...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK4588","VXUS","09887","HK0000252152.HKD","HK0000500386.USD","BK1161","IPOS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137713404","title":"Leads Biolabs Calls 15 May 2026 AGM; Reports 2025 Results, Proposes No Dividend and Seeks Fresh Share Issue & Buy-back Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1137713404","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137713404?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:24","pubTimestamp":1777040687,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, 09887) has issued a circular convening its Annual General Meeting for 10:00 a.m. on 15 May 2026 in Nanjing. Key items on the agenda are summarised...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167235046","title":"Leads Biolabs Publishes 2026 AGM Agenda: 2025 Results, EY Re-appointment, Share Mandates and Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1167235046","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167235046?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:23","pubTimestamp":1777040585,"startTime":"0","endTime":"0","summary":"Leads Biolabs (南京維立志博生物科技股份有限公司) has issued the proxy form and agenda for its Annual General Meeting (AGM) scheduled for 10:00 a.m. on Friday, 15 May 2026, at the Company’s headquarters on Floor 6,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629842704","title":"Nanjing Leads Biolabs publishes ESG report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629842704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629842704?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:46","pubTimestamp":1777038418,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs released its first ESG report, outlining governance, innovation, workforce, climate, and supply-chain priorities for fiscal 2025.Revenue totaled RMB 177 million, with new licensing deals carrying potential value above USD 1 billion.Core product LBL-024 completed pivotal trial enrollment, with first China BLA targeted for Q3 2026.Corporate governance metrics included 0 material information security incidents, 0 material legal violations, 58 investor announcements since listing.Environmental indicators showed 100% compliant hazardous waste disposal, with per-capita water use down 9.6% year over year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL9Rhvn0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175502404","title":"Leads Biolabs Proposes House-Keeping Amendments to Its Articles of Association, Seeks Shareholder Approval at Upcoming AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1175502404","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175502404?lang=en_us&edition=fundamental","pubTime":"2026-04-24 18:28","pubTimestamp":1777026511,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) has released an announcement detailing plans to refine multiple clauses in its Articles of Association. The proposed changes are positioned as...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629176348","title":"Nanjing Leads Biolabs proposes articles of association amendments for shareholder approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2629176348","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629176348?lang=en_us&edition=fundamental","pubTime":"2026-04-24 18:12","pubTimestamp":1777025553,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs proposed amendments to articles of association, subject to a special resolution at upcoming annual general meeting.Changes update share buyback provisions, including approval thresholds for board action plus timelines for cancellation or transfer of repurchased shares.Revisions also adjust cross-references in sections covering external guarantees, shareholder meeting procedures, senior management eligibility, and liquidation triggers.Board plans to seek authority to fine-tune wording to meet any regulatory requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDLMBTts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629037319","title":"Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Opamtistomig (Lbl-024) Enters Phase Ⅱ Trial With First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629037319?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:47","pubTimestamp":1776779229,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nTUA3MNBBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172645376","title":"LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1172645376","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172645376?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:50","pubTimestamp":1776761442,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating LBL-024, a PD-L1/4-1BB bispecific antibody, for the treatment of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4023","BK4588","BK4099","HK0000252152.HKD","BK4604","LU1169589451.USD","PD","HK0000252160.HKD","LU1169590202.USD","TM","BK4585","HK0000500386.USD","03160","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":101,"code":"91000000","status":"200"}]}}